| Title: | Polygenicity of Comorbid Depression in Multiple Sclerosis |
| Journal: | Neurology |
| Published: | 8 Jun 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37290970/ |
| DOI: | https://doi.org/10.1212/wnl.0000000000207457 |
| URL: | https://n.neurology.org/content/neurology/101/5/e522.full.pdf |
| Citations: | 3 (3 in last 2 years) as of 8 Aug 2024 |
Publication 11541
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND AND OBJECTIVES: Depression is common in multiple sclerosis (MS) and is associated with faster disability progression. The etiology of comorbid depression in MS remains poorly understood. Identification of individuals with a high risk of depression, through polygenic scores (PGS), may facilitate earlier identification. Previous genetic studies of depression considered depression as a primary disorder, not a comorbidity, and thus, findings may not generalize to MS. Body mass index (BMI) is a risk factor of both MS and depression, and its association may highlight differences in depression in MS. To improve the understanding of comorbid depression in MS, we will investigate PGS in people with MS, with the hypothesis that a higher depression PGS is associated with increased odds for comorbid depression in MS.</p>
METHODS: Samples from 3 sources (Canada, UK Biobank, and the United States) were used. Individuals were grouped into cases (MS/comorbid depression) and compared with 3 control groups: MS/no depression, depression/no immune disease, and healthy persons. We used 3 depression definitions: lifetime clinical diagnoses, self-reported diagnoses, and depressive symptoms. The PGS were tested in association with depression using regression.</p>
RESULTS: A total of 106,682 individuals of European genetic ancestry were used: Canada (n = 370; 213 with MS), UK Biobank (n = 105,734; 1,390 with MS), and the United States (n = 578 with MS). Meta-analyses revealed individuals with MS and depression had a higher depression PGS compared with both individuals with MS without depression (odds ratio range per SD 1.29-1.38, p < 0.05) and healthy controls (odds ratio range per SD 1.49-1.53, p < 0.025), regardless of the definition applied and when sex stratified. The BMI PGS was associated with depressive symptoms (p ≤ 0.001). The depression PGS did not differ between depression occurring as a comorbid condition with MS or as the primary condition (odds ratio range per SD 1.03-1.13, all p > 0.05).</p>
DISCUSSION: A higher depression genetic burden was associated with approximately 30%-40% increased odds of depression in European genetic ancestry participants with MS compared with those without depression and was no different compared with those with depression and no comorbid immune disease. This study paves the way for further investigations into the possible use of PGS for assessing psychiatric disorder risk in MS and its application to non-European genetic ancestries.</p>
19 Authors
- Kaarina Kowalec
- Kathryn C Fitzgerald
- Amber Salter
- Casandra Dolovich
- Arvid Harder
- Charles N Bernstein
- James Bolton
- Gary R Cutter
- Lesley A Graff
- Sara Hägg
- Carol A Hitchon
- Yi Lu
- Fred Lublin
- Kyla A McKay
- Scott B Patten
- Amit Patki
- Hemant K Tiwari
- Jerry S Wolinsky
- Ruth Ann Marrie
Enabling scientific discoveries that improve human health